^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-A2102

    i
    Other names: SHR-A2102, SHRA2102, SHR A2102
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, Nectin-4-targeted antibody-drug conjugate
    Related drugs:
    4d
    A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P3, N=402, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P3 trial • Metastases
    |
    gemcitabine • paclitaxel • docetaxel • pemetrexed • SHR-A2102
    12d
    SHR-A2102-208: A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy (clinicaltrials.gov)
    P2, N=100, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    SHR-A2102
    1m
    A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    CS1002 (ipilimumab biosimilar) • SHR-A2102 • Ariely (adebrelimab)
    1m
    A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=124, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SHR-A2102 • Ariely (adebrelimab)
    2ms
    A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P2 trial • Metastases
    |
    SHR-A2102
    2ms
    Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, Fudan University
    New P2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 expression
    |
    trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
    2ms
    A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    SHR-A2102 • Ariely (adebrelimab)
    3ms
    BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov)
    P2, N=620, Recruiting, Fudan University | N=140 --> 620
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Avastin (bevacizumab) • sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • SHR-A2102 • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
    3ms
    A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=124, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    SHR-A2102 • Ariely (adebrelimab)
    4ms
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=248, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    cisplatin • carboplatin • SHR-A2102 • Ariely (adebrelimab)
    5ms
    Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Fudan University
    New P2 trial • Metastases
    |
    trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • HRS-4642 • SHR-A1904
    5ms
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=248, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial • Metastases
    |
    cisplatin • carboplatin • SHR-A2102 • Ariely (adebrelimab)
    6ms
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer (clinicaltrials.gov)
    P1/2, N=148, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    cisplatin • SHR-A2102 • Ariely (adebrelimab)
    6ms
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer (clinicaltrials.gov)
    P1/2, N=148, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial • Metastases
    |
    cisplatin • SHR-A2102 • Ariely (adebrelimab)
    7ms
    A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=80, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial • Metastases
    |
    SHR-A2102 • Ariely (adebrelimab)
    over1year
    Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=200, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    SHR-A2102